1. Home
  2. NUWE vs CMND Comparison

NUWE vs CMND Comparison

Compare NUWE & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

N/A

Current Price

$3.77

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

N/A

Current Price

$3.04

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUWE
CMND
Founded
1999
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.2M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
NUWE
CMND
Price
$3.77
$3.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.4M
5.2K
Earning Date
11-12-2026
09-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $8,270,000.00
N/A
Revenue This Year
$19.32
N/A
Revenue Next Year
$12.01
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.07
52 Week High
$222.30
$7.16

Technical Indicators

Market Signals
Indicator
NUWE
CMND
Relative Strength Index (RSI) 40.20 24.30
Support Level $0.28 $0.58
Resistance Level $5.74 $4.66
Average True Range (ATR) 0.51 0.43
MACD 0.02 -0.41
Stochastic Oscillator 0.86 0.32

Price Performance

Historical Comparison
NUWE
CMND

About NUWE Nuwellis Inc.

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

Share on Social Networks: